<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600558/" ref="ordinalpos=1487&amp;ncbi_uid=4719788&amp;link_uid=PMC3600558" image-link="/pmc/articles/PMC3600558/figure/F3/" class="imagepopup">Figure 3. Immunoblotting for EGFR-related <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> proteins in the Tu212 cell line.  From: The Sequence Dependence of Cell Growth Inhibition by EGFR-Tyrosine Kinase Inhibitor ZD1839, Docetaxel and Cisplatin in Head and Neck Cancer. </a></div><br /><div class="p4l_captionBody">Z and any of its combinations efficiently inhibit the EGFR-mediated signaling pathways involving ERK and AKT.</div></div>